The UAE Lung Cancer Drug Market is projected to grow from $48 Mn in 2022 to $97 Mn by 2030, registering a CAGR of 9.3% during the forecast period of 2022 - 2030. According to the World Health Organization (WHO), lung cancer is the second most common cancer in both men and women in the UAE, accounting for 13% of all cancer cases. Some of the major local players in the UAE lung cancer drug market include Emirates Pharmaceutical Industries, Gulf Pharmaceutical Industries, and Julphar.
The UAE Lung Cancer Drug Market is projected to grow from $48 Mn in 2022 to $97 Mn by 2030, registering a CAGR of 9.3% during the forecast period of 2022 - 2030.
The pharmaceutical market in the United Arab Emirates (UAE) is one of the most developed in the Middle East and North Africa (MENA) region. The market is valued at around $3 billion and is expected to continue growing at a steady rate in the coming years. The UAE government has been actively promoting the development of the pharmaceutical industry and has implemented various initiatives to support the growth of domestic production and attract foreign investment. The government has also implemented regulations to ensure the quality and safety of pharmaceutical products in the country. The main players in the UAE pharmaceutical market include local and international companies, with a significant presence of generic drug manufacturers. The market is primarily driven by factors such as a growing population, increasing healthcare expenditure, and a rise in chronic diseases.
Lung cancer is one of the most common types of cancer in the United Arab Emirates (UAE). According to the World Health Organization (WHO), lung cancer is the second most common cancer in both men and women in the UAE, accounting for 13% of all cancer cases. The incidence of lung cancer in the UAE is relatively high compared to other countries in the region and is likely due to a combination of factors such as high rates of smoking, exposure to environmental pollutants, and genetic predisposition.
Tobacco use is one of the main risk factors for lung cancer in the UAE, with smoking rates being higher among men than women. According to a study conducted by the UAE Ministry of Health and Prevention, around 22% of adult men in the UAE smoke tobacco. The study also found that the prevalence of smoking among men decreases with age, but increases with education level and income.
The UAE government has implemented various measures to reduce the incidence of lung cancer in the country, such as implementing a nationwide tobacco control program, raising taxes on tobacco products, and increasing public awareness about the dangers of smoking.
In terms of treatment, lung cancer patients in UAE have access to advanced diagnostic and therapeutic options, including surgery, radiation therapy, and chemotherapy. The country has well-equipped cancer centers and hospitals to provide cancer treatment.
Market Drivers
There are several key drivers of the lung cancer drug market in the United Arab Emirates (UAE):
Key Players
The key players in the UAE lung cancer drug market include a mix of local and international pharmaceutical companies. Some of the major players in the market include:
Local pharmaceutical companies: Some of the major local players in the UAE lung cancer drug market include Emirates Pharmaceutical Industries, Gulf Pharmaceutical Industries, and Julphar. They also offer a range of lung cancer drugs and other cancer drugs.
It's worth noting that the above-mentioned companies are some of the key players in the lung cancer drug market, but there are also other local and international companies with a presence in the UAE that also offer lung cancer drugs, as well as other cancer drugs.
The United Arab Emirates (UAE) has a healthcare system that is considered to be one of the most advanced in the Middle East. The country's healthcare system is regulated by the Ministry of Health and Prevention (MOHAP) and the Dubai Health Authority (DHA). The MOHAP and DHA are responsible for setting healthcare policies, regulations, and guidelines, including those related to the approval and reimbursement of drugs for lung cancer.
In terms of reimbursement, the UAE has a national formulary that lists the drugs that are covered by the country's national health insurance scheme. Drugs for lung cancer are generally covered by the national health insurance scheme, but the specific drugs that are covered may vary depending on the stage and type of cancer.
In terms of approval, the UAE follows a centralized process for the registration of drugs. The MOHAP is responsible for the registration of drugs in the country and the DHA is responsible for the registration of drugs in Dubai. The process for registering a drug in the UAE typically involves submitting an application to the MOHAP or DHA, along with clinical trial data and other relevant information. The MOHAP or DHA will then review the application and make a decision on whether to approve the drug for use in the country.
Overall, the UAE has a well-established healthcare system with regulations and policies that are in place to ensure the safety and efficacy of drugs for lung cancer.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Disease type
By Drug
By End-user
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?